[go: up one dir, main page]

AR087273A1 - 3-(fluorovinil)pirazoles y su uso - Google Patents

3-(fluorovinil)pirazoles y su uso

Info

Publication number
AR087273A1
AR087273A1 ARP120102653A ARP120102653A AR087273A1 AR 087273 A1 AR087273 A1 AR 087273A1 AR P120102653 A ARP120102653 A AR P120102653A AR P120102653 A ARP120102653 A AR P120102653A AR 087273 A1 AR087273 A1 AR 087273A1
Authority
AR
Argentina
Prior art keywords
alkyl
fluorine
cycloalkyl
series
alkoxy
Prior art date
Application number
ARP120102653A
Other languages
English (en)
Inventor
Hrter Michael Dr
Beck Hartmut Dr
Thierauch Karl Dr
Ellinghaus Peter Heinz-Dr
Greschat Susanne Dr
Schuhmacher Joachim Dr
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of AR087273A1 publication Critical patent/AR087273A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Procedimientos para su preparación, a su uso para el tratamiento y/o la prevención de enfermedades así como a su uso para la preparación de medicamentos para el tratamiento y/o la prevención de enfermedades, especialmente para el tratamiento y/o la prevención de enfermedades hiperproliferativas y angiogénicas así como aquellas enfermedades que se producen debido a una adaptación metabólica a estados de hipoxia. Tales tratamientos puede realizarse como monoterapia o también en combinación con otros medicamentos u otras medidas terapéuticas.Reivindicación 1: Compuesto de la fórmula (1) en la que uno de los dos restos R1A y R1B representa flúor y el otro representa hidrógeno; Ar con el sustituyente R2 representa un anillo fenilo o piridilo del grupo de fórmulas (2), en la que * marca el punto de unión con el grupo CH2 adyacente; R2 representa hidrógeno o un sustituyente seleccionado de la serie halógeno, ciano, alquilo C1-6, alquenilo C2-6, cicloalquilo C3-6, alcoxi C1-6, cicloalcoxi C3-6, alcoxicarbonilo C1-4, alquilsulfonilo C1-4, -NR5R6 y -C(=O)-NR5R6, pudiendo alquilo C1-6 a su vez estar hasta trisustituido con flúor así como hasta disustituido, de manera igual o diferente, con un resto seleccionado de la serie hidroxi, alcoxi C1-4, alquilcarboniloxi C1-4 y cicloalquilo C3-6 y los grupos cicloalquilo mencionados a su vez puedan estar hasta disustituidos, de manera igual o diferente, con un resto seleccionado de la serie flúor, alquilo C1-4, trifluorometilo, hidroxi, hidroximetilo, alcoxi C1-4 y alquilcarboniloxi C1-4, y en la que R5 y R6 independientemente entre sí significan hidrógeno, alquilo C1-6 o cicloalquilo C3-6 o R5 y R6 están enlazados entre sí y junto con el átomo de nitrógeno al que están unidos forman un heterociclo de 4 - 6 miembros, que puede contener otro heteroátomo de la serie N, O, S o S(O)2 y que puede estar hasta disustituido, de manera igual o diferente, con un resto seleccionado de la serie flúor, ciano, hidroxi, alcoxi C1-4, oxo, alquilo C1-4 y cicloalquilo C3-6, pudiendo alquilo C1-4 a su vez estar hasta trisustituido con flúor; R3 representa un sustituyente seleccionado de la serie halógeno, ciano, pentafluorotio, tri-alquilsililo C1-4, alquilo C1-6, -NR7R8, -OR8, -SR8, -S(O)2-R8, cicloalquilo C3-6 y heterociclilo de 4 a 6 miembros, pudiendo alquilo C1-6 a su vez estar sustituido con un resto seleccionado de la serie amino, -NR7R8, hidroxi, -OR8, cicloalquilo C3-6 y heterociclilo de 4 a 6 miembros así como hasta sustituido seis veces con flúor y los grupos cicloalquilo y heterociclilo mencionados a su vez pueden estar hasta disustituidos, de manera igual o diferente, con un resto seleccionado de la serie flúor, alquilo C1-4, trifluorometilo, hidroxi y alcoxi C1-4, y en la que R7 significa hidrógeno o alquilo C1-4 y R8 significa alquilo C1-6 o cicloalquilo C3-6, pudiendo alquilo C1-6, a su vez estar sustituido con un resto seleccionado de la serie hidroxi, alcoxi C1-4, -NR9R10 y -C(=O)-NR9R10 así como hasta trisustituido con flúor, en el que R9 y R10 independientemente entre sí representan hidrógeno o alquilo C1-4 o están enlazados entre sí y junto con el átomo de nitrógeno, al que están unidos, forman un anillo de pirrolidina, piperidina o morfolina; y A representa N o C-R4 en el que R4 significa hidrógeno, flúor, cloro, ciano, metilo, trifluorometilo o metoxi; así como sus sales, solvatos y solvatos de las sales.
ARP120102653A 2011-07-21 2012-07-20 3-(fluorovinil)pirazoles y su uso AR087273A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11174843 2011-07-21

Publications (1)

Publication Number Publication Date
AR087273A1 true AR087273A1 (es) 2014-03-12

Family

ID=46514386

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102653A AR087273A1 (es) 2011-07-21 2012-07-20 3-(fluorovinil)pirazoles y su uso

Country Status (6)

Country Link
US (1) US20130150325A1 (es)
EP (1) EP2734505A1 (es)
AR (1) AR087273A1 (es)
CA (1) CA2842352A1 (es)
UY (1) UY34200A (es)
WO (1) WO2013011033A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160434A1 (es) 2013-09-09 2016-05-25 Peloton Therapeutics Inc Eteres de arilo y sus usos
ES2737148T3 (es) 2013-12-16 2020-01-10 Peloton Therapeutics Inc Análogos de sulfona y sulfoximina cíclicos y usos de los mismos
MA40281B1 (fr) 2014-06-03 2018-11-30 Idorsia Pharmaceuticals Ltd Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
WO2016145032A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
EP3268362B1 (en) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof
EP3554490B1 (en) 2016-12-16 2022-02-16 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
EP3577099B1 (en) 2017-02-06 2024-01-24 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
CN111007182B (zh) * 2019-12-30 2022-03-25 山东华安新材料有限公司 一种气相色谱法测定2,2-二氟乙醇中杂质的方法
MX2023003245A (es) 2020-09-18 2023-04-11 Sumitomo Pharma Co Ltd Derivados de amina novedosos.
CN116183772B (zh) * 2023-03-03 2023-09-15 华夏生生药业(北京)有限公司 一种原料药中致突变杂质检测方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1466572A (zh) 2000-07-28 2004-01-07 ס����ҩ��ʽ���� 吡咯衍生物
HUP0302306A3 (en) 2000-10-05 2005-02-28 Bayer Ag Propionic acid derivatives with ppar-alpha activating properties
US6759428B2 (en) 2001-12-04 2004-07-06 Roche Palo Alto Llc Indole nitriles
US7192976B2 (en) * 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
EP2117311A4 (en) 2007-02-08 2011-05-11 Merck Sharp & Dohme Therapeutic agents
KR20100016617A (ko) 2007-05-18 2010-02-12 바이엘 쉐링 파마 악티엔게젤샤프트 과증식성 장애 및 혈관형성 관련 질환의 치료에 유용한 저산소증 유도성 인자 （ｈｉｆ）의 억제제
CA2685716A1 (en) 2008-04-04 2009-10-08 Summit Corporation Plc Compounds for treating muscular dystrophy
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
WO2010054764A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heteroaromatische verbindungen zur verwendung als hif-inhibitoren
HRP20150341T1 (hr) 2008-11-14 2015-05-08 Bayer Intellectual Property Gmbh Heterocikliäśki supstituirani spojevi arila kao inhibitori hif

Also Published As

Publication number Publication date
WO2013011033A1 (de) 2013-01-24
US20130150325A1 (en) 2013-06-13
UY34200A (es) 2013-02-28
EP2734505A1 (de) 2014-05-28
CA2842352A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
AR087273A1 (es) 3-(fluorovinil)pirazoles y su uso
AR067646A1 (es) Ariloxazoles sustituidos y su uso
AR047449A1 (es) Amino-benzazoles como inhibidores del receptor p2y1, composiciones farmaceuticas y metodos de tratamiento
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
UY37848A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
AR074336A1 (es) Compuestos de arilo con sustituyentes heterociclicos y su uso
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
CY1119383T1 (el) Αναστολεας ανθρωπινης ιστονικης μεθυλοτρανσφερασης εζη2 σε μορφη αλατος
UY37845A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
AR092924A1 (es) Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
PE20142098A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
AR059338A1 (es) N-fenilbenzotriazolilo como inhibidores de c-kit
MX2015009602A (es) Piridona amidas como moduladores de canales de sodio.
CU20110145A7 (es) Derivados de sulfonamida
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
MX2017015741A (es) Moduladores de ror gamma (ror?).

Legal Events

Date Code Title Description
FA Abandonment or withdrawal